MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202647082984 A) filed by Heidelberg Pharma Research Gmbh on July 06, 2026, for Modular Linker Compound For Target-Binding Drug Conjugates.
Inventors include Mller, Christoph; Gruss, Hendrik; Hechler, Torsten; and Petrich, Valentin.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: The present invention relates to modular linker compounds for target-binding drug conjugates (TBDCs) and in particular to modular linker compounds for antibody-drug-conjugates (ADCs). The modular linker compounds comprise solubility enhancing groups and self-immolative spacers. The invention further relates to methods of synthesizing the modular linker compound, to target-binding drug conjugates comprising the modular linker compound of the invention as well as to pharmaceutical compositions comprising target- binding drug conjugates compound of the invention. Embodiments of the invention have been particularly developed as target-binding drug conjugates for use in the treatment of cancer and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
Disclaimer: Curated by HT Syndication.
